Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Cipher Mining Inc (CIFR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Cipher Mining Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Cipher Mining Inc trades at $21.89 (market cap $9.04B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.4× Cipher Mining Inc's market cap, and Cipher Mining Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CIFR | |
|---|---|---|
Market Cap | $39.89B | $9.04B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $29.18 |
52-Week Low | $278.09 | $4.72 |
Enterprise Value | $38.15B | $13.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Cipher Digital (CIFR) trades at $22.11, down 4.94% today, amid a transition from Bitcoin mining to AI data center operations. The stock shows a bullish technical trend with strong analyst support (100% buy ratings) and a $32.81 consensus price target. However, fundamentals reveal deep losses with a -427.79% net income margin and negative cash flow from operations, offset by a promising $11.4B contracted revenue backlog from hyperscale leases.
The outlook hinges on successful execution of its AI infrastructure pivot, offering substantial upside if revenue ramps as planned by 2027. Key risks include persistent cash burn, high debt-to-asset ratio (64.51%), and reliance on future lease performance. Investors should weigh the growth potential against the company's current financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Cipher Mining Inc
Cipher Mining is an industrial-scale technology company focused on Bitcoin mining infrastructure. It develops and operates data centers in the US designed to strengthen the Bitcoin network and support decentralized finance.
Read more on CIFR →
